ArticleFrontiers in pharmacology2025
Caffeic acid phenethyl ester alleviates 1,2-dichloroethane-induced toxic cerebral edema: central and peripheral mechanisms.
Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: 1,2-Dichloroethane (1,2-DCE) is a widespread environmental contaminant as well as a frequent occupational hazard. Given that inflammation and oxidative stress are key mechanisms in 1,2-DCE-induced cerebral edema, we investigated the efficacy of caffeic acid phenethyl ester (CAPE), a natural anti-inflammatory and antioxidant agent known to protect blood-brain barrier (BBB) integrity, against this intoxication and explored its underlying mechanisms. Methods: Static inhalation exposure was used to establish a mouse model of 1,2-DCE-induced toxic cerebral edema. Cerebral edema was evaluated based on brain water content, histopathological changes, and tight junction proteins (TJPs) expression. The related anti-inflammatory and antioxidant mechanisms were analyzed by examining the p38 mitogen-activated protein kinase (p38 MAPK) and nuclear factor erythroid 2-related factor 2 (Nrf2) pathways, respectively. Additionally, the levels of specific cytokines and oxidative stress markers were quantified in both brain tissue and serum. Results: CAPE alleviated the body weight loss and reduced the brain water content in 1,2-DCE-intoxicated mice. Hematoxylin and eosin (HE) staining revealed that CAPE effectively ameliorated the characteristic pathological manifestations of brain edema. CAPE mediated its protective effects through the downregulation of both the p38 MAPK and Nrf2 signaling pathways, resulting in suppressed expression of the cytokines tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β), and matrix metalloproteinase-9 (MMP-9), normalized levels of glutathione (GSH) and malondialdehyde (MDA), and attenuated loss of the TJPs Occludin and ZO-1. Furthermore, CAPE reversed the 1,2-DCE-induced alterations in pro-inflammatory cytokines and oxidative stress markers in peripheral serum, while inhibiting the expression of vascular cell adhesion molecule-1 (VCAM-1) and intercellular adhesion molecule-1 (ICAM-1) in brain tissue. Conclusion: This study provides the first evidence that CAPE effectively alleviates cerebral edema through mitigating both peripheral and central inflammatory responses and oxidative stress induced by 1,2-DCE.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.